MX2024008619A - Composiciones y métodos para el tratamiento de la depresión. - Google Patents

Composiciones y métodos para el tratamiento de la depresión.

Info

Publication number
MX2024008619A
MX2024008619A MX2024008619A MX2024008619A MX2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A
Authority
MX
Mexico
Prior art keywords
methods
depression
compositions
treatment
patient
Prior art date
Application number
MX2024008619A
Other languages
English (en)
Spanish (es)
Inventor
Wayne C Drevets
Hartmuth Christian Kolb
Ziad Serhal Saad
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2024008619A publication Critical patent/MX2024008619A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4737C-reactive protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024008619A 2022-01-10 2023-01-09 Composiciones y métodos para el tratamiento de la depresión. MX2024008619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263298060P 2022-01-10 2022-01-10
PCT/IB2023/050171 WO2023131921A1 (en) 2022-01-10 2023-01-09 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
MX2024008619A true MX2024008619A (es) 2024-09-25

Family

ID=84981673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008619A MX2024008619A (es) 2022-01-10 2023-01-09 Composiciones y métodos para el tratamiento de la depresión.

Country Status (10)

Country Link
US (1) US20250064779A1 (https=)
EP (1) EP4463143A1 (https=)
JP (1) JP2025503649A (https=)
KR (1) KR20240132501A (https=)
CN (1) CN118843459A (https=)
AU (1) AU2023206048A1 (https=)
CA (1) CA3247733A1 (https=)
IL (1) IL314176A (https=)
MX (1) MX2024008619A (https=)
WO (1) WO2023131921A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ,インコーポレーテッド エスケタミンの鼻腔内投与

Also Published As

Publication number Publication date
EP4463143A1 (en) 2024-11-20
KR20240132501A (ko) 2024-09-03
CN118843459A (zh) 2024-10-25
IL314176A (en) 2024-09-01
JP2025503649A (ja) 2025-02-04
US20250064779A1 (en) 2025-02-27
WO2023131921A1 (en) 2023-07-13
CA3247733A1 (en) 2023-07-13
AU2023206048A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CL2023003259A1 (es) Composiciones y métodos para el tratamiento de la depresión.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
JOP20230157A1 (ar) طرق مُعالجة فيروس كورونا
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112017003552A2 (pt) ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?
BR112023002668A2 (pt) Composições e métodos para tratar cânceres egfr positivos
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
CO2022014199A2 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19
MX2024010980A (es) Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2024008619A (es) Composiciones y métodos para el tratamiento de la depresión.
BR112023024701A2 (pt) Métodos de tratamento de doenças do fígado
EA200501803A1 (ru) Сочетание аналептика модафинила и антидепрессанта для лечения депрессии
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria
MX2024015839A (es) Composiciones y usos de psilocibina y psilocina
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
BR112022026070A2 (pt) Terapia combinada de verapamil e mometasona para o tratamento de rinosinosinusite crônica
BR112023022273A2 (pt) Agrupamentos de ouro, composições e métodos para tratamento de depressão